Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Relmada Therapeutics Q1 2026 Earnings Call - Phase III RESCUE Program on Track with $160 Million War Chest and Compelling 12-Month Bladder Cancer Data
Relmada Therapeutics entered the second half of 2026 with a fortified balance sheet and clear regulatory pathways. The company secured $160 million in private financing, pushing its cash position to $...
- Relmada closed Q1 2026 with a cash balance of $234 million, following a $160 million private placement completed in March 2026. This fortifies the balance sheet and provides sufficient runway to fund operations and complete the Phase III RESCUE program through 2029.
- The company remains on track to initiate the Phase III RESCUE registrational program for NDV-01 in mid-2026, following successful FDA alignment on the trial design and endpoints.
- NDV-01, a sustained-release intravesical formulation of gemcitabine and docetaxel, demonstrated a 76% complete response (CR) rate at 12 months in the overall Phase II population of high-risk non-muscle invasive bladder cancer (NMIBC).
- +9 more takeaways
Stereotaxis Q1 2026 Earnings Call - New Disposable Ecosystem Begins to Replace Legacy J&J Supply
Stereotaxis is navigating a painful but structurally transformative transition. The company is actively winding down its two-decade-old dependency on Johnson & Johnson catheters while rolling out an e...
- Revenue of $6.3 million in Q1 2026, down from $7.5 million year-ago, reflecting a transitional period as legacy J&J catheter supply winds down before the new disposable ecosystem scales.
- Management is actively replacing a 20-year dependency on Johnson & Johnson catheters with a new proprietary disposable business, expecting annual revenue to surpass $40 million with double-digit growth.
- Initial MAGiC catheter procedures are generating $5,000 to $8,000 in recurring revenue per case, a massive step-up from legacy hardware sales, with European hospitals already ordering $100,000 in disposables for a single month.
- +9 more takeaways
TriSalus Life Sciences Q1 2026 Earnings Call - Landmark Real-World Evidence Validates PEDD, Commercial Expansion Drives Revenue Transition
TriSalus Life Sciences reported a deliberate but costly transition in its first quarter, as a massive commercial expansion temporarily disrupted sales while laying the groundwork for future growth. Re...
- Revenue for Q1 2026 was $8.9 million, slightly down from $9.2 million in the prior year period, primarily due to transition costs associated with a major commercial expansion.
- Gross margin improved to 86% from 84% in the prior year, driven by lower average unit costs on TriNav and continuous manufacturing improvements.
- The company is executing a deliberate commercial realignment, doubling its sales force and expanding its territory footprint to capture growth across a $2.5 billion addressable market.
- +11 more takeaways
GrowGeneration Q1 2026 Earnings Call - Commercial B2B Momentum and Proprietary Brand Expansion Drive Revenue Growth
GrowGeneration delivered its second consecutive quarter of year-over-year revenue growth in Q1 2026, with net sales rising 7.5% to $38.4 million. The company’s strategic pivot toward a commercially dr...
- GrowGeneration reported Q1 2026 net sales of $38.4 million, up 7.5% year-over-year, marking its second consecutive quarter of revenue growth.
- Proprietary brand sales now represent 37% of cultivation and gardening revenue, up from 32% in the prior year, reflecting a strategic shift toward higher-margin, recurring consumable products.
- The storage solutions segment drove significant growth, with net sales increasing 35.5% year-over-year to $6.5 million, benefiting from increased capital investment across broader end markets.
- +7 more takeaways
a.k.a. Brands Q1 2026 Earnings Call - Gross Margin Expansion Signals Structural Turnaround
a.k.a. Brands delivered a resilient first quarter, with net sales rising 3% to $132.5 million and Adjusted EBITDA jumping to $5.1 million, well above prior expectations. The headline story is the 180 ...
- Net sales grew 3% year-over-year to $132.5 million, slightly ahead of company guidance, driven by 3.2% U.S. sales growth and 3.8% Australian sales growth.
- Adjusted EBITDA more than doubled to $5.1 million from $2.7 million, with the margin expanding 180 basis points to 3.9%.
- Underlying gross margin expanded 180 basis points to 59%, fueled by inventory discipline, stronger full-price sell-through, and the rollout of the test-and-repeat model, primarily in the streetwear division.
- +7 more takeaways
Fractyl Health Q1 2026 Earnings Call - Pivotal Data Countdown and Capital Discipline
Fractyl Health reported a shift to net income in Q1 2026, driven by a $30.1 million non-cash accounting adjustment, while maintaining a disciplined cash runway into early 2027. The company is advancin...
- Revita Pivotal Trial on Track: The REMAIN-1 pivotal study completed randomizations in February with over 300 participants across 30+ sites. Top-line 6-month data is expected in early Q4 2026, with management targeting a strong result defined as roughly a 50% reduction in weight regain compared to the expected 15% rebound in GLP-1 discontinuers.
- Capital Discipline and Runway: Fractyl Health holds approximately $63.2 million in cash and cash equivalents as of March 31, 2026. Management explicitly closed its ATM facility and committed to no capital raises before pivotal data, extending runway into early 2027 to fund operations and the Rejuva program.
- Rejuva Gene Therapy Advances: Fractyl received authorization from the Netherlands to initiate the phase I/II first-in-human study for RJVA-001, an AAV-based gene therapy for type 2 diabetes. First patient dosing is expected in H2 2026, funded within existing cash runway.
- +7 more takeaways
Hyperfine Q1 2026 Earnings Call - Revenue Jumps 83% as Ultra-Low Field MRI Platform Expands into Neurology Offices and International Markets
Hyperfine delivered a formidable start to 2026, posting $3.9 million in revenue, a sharp 83% year-over-year jump driven by strong demand for its next-generation Swoop subsystem across hospitals and ne...
- Revenue surged 83% year-over-year to $3.9 million, marking the second-highest quarter in company history and driven by the third full quarter of next-generation subsystem sales.
- Gross margin expanded to 50.7% from 41.3% in the prior year period, representing 940 basis points of improvement and marking the third consecutive quarter above 50%.
- Cash burn declined 13% to $8.8 million, down from $10.1 million in Q1 2025, as management enforced spending discipline and realized benefits from prior restructuring.
- +7 more takeaways
Tenon Medical Q1 2026 Earnings Call - Gross Margin Expansion Hits 68.5% on Dual-Platform Growth
Tenon Medical reported a record first quarter in 2026, with revenue nearly doubling year-over-year to $1.4 million and gross margins expanding sharply to 68.5%. The surge was driven by higher Catamara...
- Revenue surged 90% year-over-year to $1.4 million, marking the highest first-quarter revenue in company history.
- Gross margin expanded 24 percentage points to 68.5%, up from 44.5% in Q1 2025, driven by better fixed-cost absorption and operational efficiency.
- SImmetry+ contributed meaningfully to revenue for the first full quarter following the SiVantage asset acquisition in August 2025.
- +7 more takeaways
HireQuest Q1 2026 Earnings Call - Demand Stabilizes, M&A Pressure Builds
HireQuest delivered a resilient first quarter, with total revenue of $6.5 million and adjusted net income of $0.13 per share. The company’s franchise model insulated it from the broader staffing indus...
- Total revenue of $6.5 million in Q1 2026, down 12.7% year-over-year, primarily due to the January divestiture of MRI Network permanent placement assets.
- Adjusted net income held steady at $0.13 per share, with adjusted EBITDA of $2.7 million, demonstrating margin resilience despite macro headwinds.
- System-wide sales fell to $102.6 million from $118.4 million, but excluding divestiture impact, underlying sales were nearly flat year-over-year, signaling stabilization.
- +7 more takeaways
SideChannel Q2 FY2026 Earnings Call - Deliberate Revenue Decline Fuels Platform Transition
SideChannel reported a 11.9% year-over-year revenue decline to $1.58 million in Q2 FY2026, driven by a 28.4% drop in vCISO services revenue. Management framed this not as a setback, but as an intentio...
- Total revenue declined 11.9% year-over-year to $1.58 million in Q2 FY2026, missing prior growth trajectories.
- vCISO services revenue fell 28.4% year-over-year, reflecting a deliberate pullback from hourly consulting engagements.
- Gross margin expanded 380 basis points to 53.5%, demonstrating early operational leverage as the company shifts to platform models.
- +9 more takeaways